+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Validation of a short questionnaire in English and French for use in patients with persistent upper gastrointestinal symptoms despite proton pump inhibitor therapy: the PASS (Proton pump inhibitor Acid Suppression Symptom) test



Validation of a short questionnaire in English and French for use in patients with persistent upper gastrointestinal symptoms despite proton pump inhibitor therapy: the PASS (Proton pump inhibitor Acid Suppression Symptom) test



Canadian Journal of Gastroenterology 19(6): 350-358



The management of persistent symptoms during acid suppression therapy in patients with gastroesophageal reflux disease or dyspepsia might be improved if patient-physician communication regarding the presence and character of these persistent symptoms were facilitated. To validate a short, simple questionnaire (the Proton pump inhibitor [PPI] Acid Suppression Symptom [PASS] test), in English and French, to identify patients with persistent acid-related symptoms during PPI therapy and document their response to a change in therapy. Patients with persistent acid-related symptoms on PPI therapy were interviewed to produce a draft, five-item questionnaire; content validity was evaluated by focus groups comprising English- and French-speaking patients. Psychometric validity was subsequently evaluated in a multicentre, family practice-based study of English- and French-speaking patients with persistent acid-related upper gastrointestinal symptoms despite PPI therapy. The PASS test, Global Overall Symptom scale, Gastrointestinal Symptom Rating Scale (GSRS), Quality of Life in Reflux and Dyspepsia questionnaire and Reflux Disease Questionnaire were completed at baseline and repeated after one week while patients continued their original PPI therapy. All patients then received esomeprazole 40 mg once daily for four weeks, after which all questionnaires and an evaluation of overall treatment effect were completed. Content validity was established in 20 English- and 16 French-speaking patients. Psychometric validation in 158 English- and 113 French-speaking patients revealed good-to-excellent test-retest reliability coefficients: 0.76 for English; 0.68 for French. For construct validity, the PASS test showed moderate-to-high correlation with the GSRS scale (0.51 for English; 0.43 for French). After four weeks of therapy, the PASS test score fell to zero in 30% of English- and 33% of French-speaking patients, while the Global Overall Symptom score fell to one (no symptoms) in 32% of patients (English- and French-speaking); the PASS test demonstrated good responsiveness in comparison with the GSRS, Reflux Disease Questionnaire and Quality of Life in Reflux and Dyspepsia questionnaire. The five-item PASS test is a valid tool for the evaluation of persistent acid-related symptoms in patients receiving PPI therapy. It demonstrates good content validity, test-retest reliability, responsiveness and construct validity in both English and French forms. The PASS test is a simple, clinically applicable tool for the identification of patients with persistent acid-related symptoms during therapy and the assessment of their responses to a change in therapy.

(PDF emailed within 0-6 h: $19.90)

Accession: 050926382

Download citation: RISBibTeXText

PMID: 15997268

DOI: 10.1155/2005/569368


Related references

Therapy of gastroesophageal reflux disease and functional dyspepsia overlaps with symptoms after usual-dose proton pump inhibitor: Acotiamide plus usual-dose proton pump inhibitor versus double-dose proton pump inhibitor. Journal of Gastroenterology and Hepatology 33(3): 623-630, 2017

Octreotide Added to a Proton Pump Inhibitor Versus a Proton Pump Inhibitor Alone in Nonvariceal Upper-Gastrointestinal Bleeds. Annals of PharmacoTherapy 2019: 1060028019833696, 2019

Proton pump inhibitor therapy for acetylsalicylic acid associated upper gastrointestinal symptoms, a randomised clinical trial. Digestive Disease Week Abstracts & Itinerary Planner : Abstract No T1328, 2003

Proton-pump inhibitor therapy for acetylsalicylic acid associated upper gastrointestinal symptoms: A randomized placebo-controlled trial. Alimentary Pharmacology & Therapeutics 18(1): 109-115, 1st July, 2003

Persistent acid reflux and symptoms in patients with Barrett's oesophagus on proton-pump inhibitor therapy. European Journal of Gastroenterology and Hepatology 14(11): 1187-1192, 2002

Acid-related diseases. What is the current rescue treatment of choice for Helicobacter pylori: quadruple therapy (proton pump inhibitor, bismuth, tetracycline and metronidazole) or triple therapy with proton pump inhibitor, amoxicillin and levofloxacin?. Gastroenterologia Y Hepatologia 31(6): 400-401, 2008

A novel reflux inhibitor lesogaberan (AZD3355) as add-on treatment in patients with GORD with persistent reflux symptoms despite proton pump inhibitor therapy: a randomised placebo-controlled trial. Gut 60(9): 1182-1188, 2011

Pre-endoscopic proton pump inhibitor therapy reduces recurrent adverse gastrointestinal outcomes in patients with acute non-variceal upper gastrointestinal bleeding. Alimentary Pharmacology and Therapeutics 24(8): 1247-1255, 2006

Persistent gastro-oesophageal reflux symptoms despite proton pump inhibitor therapy. Singapore Medical Journal 57(10): 546-551, 2016

Cost and burden of gastroesophageal reflux disease among patients with persistent symptoms despite proton pump inhibitor therapy: an observational study in France. Bmc Gastroenterology 13: 39, 2013

Persistent gastroesophageal reflux disease symptoms on standard proton-pump inhibitor therapy. Gastroenterology Clinics of North America 31(4 Suppl): S77-S84, 2002

Proton pump inhibitor-amoxicillin-clarithromycin versus proton pump inhibitor-amoxicillin-metronidazole as first-line Helicobacter pylori eradication therapy. Journal of Clinical Biochemistry and Nutrition 51(2): 114-116, 2012

Neoplastic progression in short-segment Barrett's oesophagus is associated with impairment of chemical clearance, but not inadequate acid suppression by proton pump inhibitor therapy. Alimentary Pharmacology and Therapeutics 40(7): 835-842, 2014

Persistent acid and bile reflux in asymptomatic patients with Barrett esophagus receiving proton pump inhibitor therapy. Archives of Surgery 139(5): 547-551, 2004

Common gastrointestinal symptoms: risks of long-term proton pump inhibitor therapy. Fp Essentials 413: 29-39, 2014